A Case of Pathologically Complete Response After Nivolumab Combined with Chemotherapy in a Gastric Cancer Patient with Virchow’s Lymph Node Metastasis

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953.
   PubMed Web of Science ®Google Scholar
• Kim SG, Seo HS, Lee HH, et al. Comparison of the Differences in Survival Rates Between the 7th and 8th Editions of the AJCC TNM Staging System for Gastric Adenocarcinoma: a Single-Institution Study of 5507 Patients in Korea. J Gastric Canc. 2017;17:212–219.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015;26:141–148.
   PubMed Web of Science ®Google Scholar
• Boku N, Ryu MH, Kato K, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, Phase 3 trial. Lancet Oncol. 2022;23:234–247.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471.
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Arigami T, Matsushita D, et al. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. World J Surg Oncol. 2020;18:179.
   PubMed Web of Science ®Google Scholar
• Kumamoto T, Tomita T, Hojo Y, et al. Pathological Complete Response and Successful Conversion Surgery After Nivolumab Therapy for Stage IV Oesophagogastric Junction Cancer. Vivo. 2021;35:2247–2251.
   PubMed Web of Science ®Google Scholar
• Dai P, Rao X, Zhang X, et al. Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery. Front Immunol. 2022;13:908558.
   PubMed Web of Science ®Google Scholar
• Vital Statistics Japan (Ministry of Health, Labour and Welfare). Center for Cancer Control and Information Services, National Cancer Center, Japan Web site. Available from: https://ganjoho.jp/reg_stat/statistics/dl/index.html. Accessed July 11, 2023.
   Google Scholar
• Nashimoto A, Akazawa K, Isobe Y, et al. Gastric Cancer Treated in 2002 in Japan: 2009 Annual Report of the JGCA Nationwide Registry. Gastric Canc. 2013;16:1–27.
   PubMed Web of Science ®Google Scholar
• Virchow RLK. Zur diagnose der krebse im unterleibe. Med Reform. 1848;45:248.
   Google Scholar
• Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Am J Surg. 2008;196:100–113.
   PubMedGoogle Scholar
• Izumo W, Furukawa K, Katsuragawa H, et al. A case of advanced gastric cancer with tumor embolus in the portal vein and liver metastasis responding to S-1 plus cisplatin chemotherapy. Nihon Shokakibyo Gakkai Zasshi. 2014;111:2131–2139.
   PubMedGoogle Scholar
• Terashima T, Yamashita T, Takabatake H, et al. Successful second conversion surgery after trastuzumab deruxtecan for recurrent HER2-positive gastric cancer. Clin J Gastroenterol. 2023. doi:10.1007/s12328-023-01764-3
   Web of Science ®Google Scholar
• Iwazawa T, Kinuta M, Yano H, et al. An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow’s metastasis to receive curative resection. Gastric Cancer. 2002;5:96–101.
   PubMedGoogle Scholar
• Holen KD, Klimstra DS, Hummer A, et al. International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2021;6:227–240.
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021. Gastric Cancer. Kanehara Publishing Co, Ltd; 2021.
   Google Scholar
• Al-Batran SE, Goetze TO, Mueller DW, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer. 2017;17:893.
   PubMed Web of Science ®Google Scholar
• Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–660.
   PubMed Web of Science ®Google Scholar
• Marker SR, Mikhail S, Malietzis G, et al. Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: systematic Review and Pooled Analysis. Ann Surg. 2016;263:1092–1101.
   PubMed Web of Science ®Google Scholar
• Kodera Y, Fujitani K, Fukushima N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17:206–212.
   PubMed Web of Science ®Google Scholar
• Bian SB, Shen WS, Xi HQ, et al. Palliative Therapy for Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer: a Meta-analysis Comparison of Gastrojejunostomy with Endoscopic Stenting. Chin Med J. 2016;129:1113–1121.
   PubMed Web of Science ®Google Scholar
• Ahmed O, Lee JH, Thompson CC, et al. AGA Clinical Practice Update on the Optimal Management of the Malignant Alimentary Tract Obstruction: expert Review. Clin Gastroenterol Hepatol. 2021;19:1780–1788.
   PubMed Web of Science ®Google Scholar
• Oida T, Mimatsu K, Kawasaki A, et al. Modified Devine exclusion with vertical stomach reconstruction for gastric outlet obstruction: a novel technique. J Gastrointest Surg. 2009;13:1226–1232.
   PubMed Web of Science ®Google Scholar
• Ramos MFKP, Barchi LC, de Oliveira RJ, et al. Gastric partitioning for the treatment of malignant gastric outlet obstruction. World J Gastrointest Oncol. 2019;11:1161–1171.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Giliberti A, Bianco M, et al. Stomach-partitioning gastrojejunostomy is better than conventional gastrojejunostomy in palliative care of gastric outlet obstruction for gastric or pancreatic cancer: a meta-analysis. J Gastrointest Oncol. 2019;10:283–291.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J. 2016;375:1856–1867.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association. Comment of Japanese gastric cancer treatment guidelines committee. Available fron: chromeextension://efaidnbmnnnibpcajpcglclefindmkaj/http://www.jgca.jp/pdf/news202112_1.pdf. Accessed July 11, 2023.
   Google Scholar
• Song YX, Huang XZ, Gao P, et al. Clinicopathologic and prognostic value of serum carbohydrate antigen 19-9 in gastric cancer: a meta-analysis. Dis Markers. 2015;2015:1–11.
   Web of Science ®Google Scholar
• Deng K, Yang L, Hu B, et al. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. PLoS One. 2015;10:1–23.
   Web of Science ®Google Scholar
• Leal A, van Grieken NCT, Palsgrove DN, et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat Commun. 2020. doi:10.1038/s41467-020-14310-3
   Web of Science ®Google Scholar
• Slagter AE, Vollebergh MA, Caspers IA, et al. Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. Gastric Cancer. 2022;25:401–410.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Nakamura Y, Kotani D, et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112:2915–2920.
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–4393.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–321.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kodera Y, Kochi M, et al. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019;37:1296–1304.
   PubMedGoogle Scholar
• Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021;32:368–374.
   PubMed Web of Science ®Google Scholar